SVRA Stock Summary and Trading Ideas (Savara | NASDAQ:SVRA)

Savara Inc is a clinical-stage biopharmaceutical company. It is focused on rare respiratory diseases. It has one segment specialty pharmaceuticals within the respiratory system. The company's main product candidate, molgramostim, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).

Savara trades on the NASDAQ stock market under the symbol SVRA.

As of July 13, 2026, SVRA stock price declined to $5.74 with 1,036,630 million shares trading.

SVRA has a beta of 1.42, meaning it tends to be more sensitive to market movements. SVRA has a correlation of 0.09 to the broad based SPY ETF.

SVRA has a market cap of $1.18 billion. This is considered a Small Cap stock.

In the last 3 years, SVRA traded as high as $7.01 and as low as $1.89.

The top ETF exchange traded funds that SVRA belongs to (by Net Assets): VTI, IWM, XBI, IWO, VXF.

SVRA has outperformed the market in the last year with a return of +149.6%, while the SPY ETF gained +20.9%. However, in the most recent history, SVRA shares have underperformed the stock market with its stock returning +1.4% in the last 3 month period and -2.7% for the last 2 week period, while SPY has returned +10.5% and +2.8%, respectively.

SVRA support price is $5.85 and resistance is $6.21 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SVRA shares will trade within this expected range on the day.